椎管内麻醉患者术后恶心呕吐相关因素与临床干预研究

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (4): 201-204.

椎管内麻醉患者术后恶心呕吐相关因素与临床干预研究

赵翠红¹, 陶怡秀¹, 王盛海¹, 赵强¹, 孟庆勇¹, 张汉湘¹, 秦明英¹, 马文霞², 弥曼²

1汉中市中心医院,陕西汉中 723000;
2西安医学院第二附属医院,陕西西安 710038

收稿日期:2018-05-29 修回日期:2018-05-29 出版日期:2018-04-20 发布日期:2018-05-29
作者简介:赵翠红,女,本科,副主任药师,临床药学。
基金资助:
陕西省卫生厅科研基金中标项目E类（2012E8）：椎弓根形态与胸腰段骨折伤椎置钉、植骨关系的研究

Study on Related Factors of Postoperative Nausea and Vomiting and Clinical Intervention in Patients with Intraspinal Anesthesia

ZHAO Cui-hong¹, TAO Yi-xiu¹, WANG Sheng-hai¹, ZHAO Qiang¹, MENG Qing-yong¹, ZHANG Han-xiang¹, QING Ming-ying¹, MA Wen-xia², MI Man²

1Hanzhong Central Hospital, Shanxi Hanzhong 723000, China;
2The Second Affiliated Hospital of Xi'an Medical University, Shanxi Xi'an 710038, China

Received:2018-05-29 Revised:2018-05-29 Online:2018-04-20 Published:2018-05-29

摘要/Abstract

摘要： 目的研究阿片类药物、5-羟色胺3（5-HT3）受体拮抗剂与术后恶心呕吐（PONV）相关性,指导临床合理用药。方法通过530例椎管内麻醉患者,研究手术患者使用阿片类药物,干预与未干预对PONV的影响及差异性,并比较了临床常用的3种5-HT3受体拮抗剂预防恶心呕吐的疗效与差异性,同时,还研究了不同阿片类药物术后PONV发生的时间特点。结果使用阿片类药物后,5-HT3受体拮抗剂干预与未干预,PONV的发生有显著差异（P<0.05）; 3种5-HT3受体拮抗剂干预PONV疗效肯定,无差异（P>0.05）;不同阿片类药物PONV发生时间集中发生在术后2~6 h之间,占69.23%~76.92%。24 h后发生机率小,占1.54%。结论 5-HT3受体拮抗剂对术中、术后恶心呕吐的预防疗效良好,3种5-HT3受体拮抗剂对术中、术后恶心呕吐的预防效果相似,考虑到经济性,临床采用昂丹司琼预防术中、术后恶心呕吐较为经济。不同阿片类药物引发PONV程度不同,无PONV高发因素,不宜预防使用5-HT3受体拮抗剂,避免过度治疗。

关键词: 阿片类药物, 术后恶心呕吐（PONV）, 5-羟色胺3受体拮抗剂（5-HT3）, 药品不良反应（ADR）

Abstract: Objective To study the relationship of PONV (postoperative nausea and vomiting) between opioids and 5-HT3 receptor antagonists to guide the clinical rational use of drugs. Methods Through the 530 cases of the use of opioids in spinal anesthesia patients, study the intervention and nonintervention effect on PONV and difference, and compare the effects of three differences kinds of 5-HT3 receptor antagonists in preventing nausea and vomiting. At the same time, the time characteristics of PONV after different opioids is also studied. Results There was a significant difference in the incidence of PONV between the use of opioids and 5-HT3 receptor antagonist (P <0.05). The effects of different 5-HT3 receptor antagonists on PONV was positive (P >0.05). The occurrence time of PONV by different opioids was basically the same, which occurred between 2~6 h postoperatively, accounting for 69.23%~76.92%. The incidence of PONV after 24 h was very small, accounting for 1.54%. Conclusion The efficacy of 5-HT3 receptor antagonist on intraoperative and postoperative nausea and vomiting prevention is good. The prevention effect of three kinds of 5-HT3 receptor antagonists on intraoperative and postoperative nausea and vomiting is similar. But take into account the economy, ondansetron is used for preventing postoperative nausea and vomiting in clinical. Different opioids lead to different levels of PONV. It is no need to use 5-HT3 receptor antagonists preventively without the high risk factor of PONV, so that to avoid overtreatment.

Key words: opioids, postoperative nausea and vomiting (PONV), 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, adverse drug reaction(ADR)

中图分类号:

R916.61

赵翠红, 陶怡秀, 王盛海, 赵强, 孟庆勇, 张汉湘, 秦明英, 马文霞, 弥曼. 椎管内麻醉患者术后恶心呕吐相关因素与临床干预研究[J]. 中国药物警戒, 2018, 15(4): 201-204.

ZHAO Cui-hong, TAO Yi-xiu, WANG Sheng-hai, ZHAO Qiang, MENG Qing-yong, ZHANG Han-xiang, QING Ming-ying, MA Wen-xia, MI Man. Study on Related Factors of Postoperative Nausea and Vomiting and Clinical Intervention in Patients with Intraspinal Anesthesia[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 201-204.

参考文献

[1] Fujii Y, Tanaka H.Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy[J]. Clin Ther, 2002,24(5):766-772.
[2] Kovac A L.Prevention and treatment of postoperative nausea and vomiting[J]. Drugs, 2005,62(12) :1261-1262.
[3] Williams K S.Postoperative nausea and vomiting[J]. Surg Clin North Am, 2005,85(6):1229-1241.
[4] Gold B,Kitz D S, Lecky J H.Unanticipated admission to the hospital following ambulatory surger[J]. FAMA, 1989,262(21):3008-3010.
[5] Kim S I, Kim S C, Baek Y H,et al.Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery[J]. Br J Anaesth, 2009,103(4):549-553.
[6] Kvles P S, Williams D L, Hendrta M, et al.Patien sarisfaction after anesthesia and surgery: Results of a prospective survey of 10811 patients[J]. Br F Anaesth, 2000,84(1):6-10.
[7] Akin A,Esmaoglu A,Gunes I,et al.The effects of the prophylactic tropisetron-propofol combination on postoperative nausea and vomiting in patients undergoing thyroidectomy under desflurane anesthesia[J]. Mt Sinai J Med, 2006,73(2):560-563.
[8] 赵翠红, 张汉湘,王盛海,等. 手术麻醉患者预防性使用 5-HT3 受体拮抗剂临床应用研究[J].中国药物警戒, 2016,13(10):587.
[9] Lovstad R Z, Thagaard K S, Berner N S, et al.Neostigmine 50microg kg(-1) with glycopyrrolate increases postoperative nau-sea in women after laparoscopic gynaecological surgery[J].Acta-Anaesthesiol Scand, 2001,45(4):495-500.
[10] Mutlu T, Hanc1 V. Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting[J]. Bars J of Anesthesiology, 2016,67(2):147-152.
[11] Alfieri A B, Cebeddu L X.Treatment with para-chlorophenylalanine antagonises the emetic response and the serotoninreleasing actions of cisplatin in cancer patients[J]. Br J Cancer, 1995,71(3): 629-632.
[12] Leslie R A, Shah Y, Thejomayen M, et al.The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting[J]. Can J Physiol Pharmacol, 1990, 68(2):279-288.
[13] Constenla M.5-HT3 receptor antagonists for prevention of late acute-onset emesis[J]. Ann Pharmacother, 2004,38(10):1683-1691.
[14] Tricco A C, Soobiah C, Antony J.Interventions to decrease the risk of adverse cardiac events for post-surgery or chemotherapy patients taking serotonin(5-HT3) receptor antagonists: protocol for a systematic review and network meta-analysis[J]. Systematic Reviews, 2013,2(45):1-5.
[15] 吕新颜, 梁茂本. 44例5-HT3受体拮抗剂不良反应文献分析[J]. 中国药物警戒, 2013,10(3):167.
[16] Yamanaga, Shigeyoshi, Posselt, et al. A Single Perioperative Injection of Dexamethasone Decreases Nausea Vomiting and Pain after Laparoscopic Donor Nephrectomy[J]. Journal of Transplantation, 2017,2017(10):1155.
[17] Schwartzberg L, Jackson J,Jain G,et al.Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting[J]. Expert Rea Pharmacoecon Outcomes Res, 2011,11(4):481-488.
[18] Baciarello M, Cornini A.Intrathecal atropine to prevent postoperative nausea and vomiting after cesarean section: A randomized, controlled trial[J]. Minerva anestesiologica, 2011, 77(8):781-788.
[19] Gregory R E, Ettinger D S.5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting[J]. Drugs, 1998,55(2):173-189.
[20] Jamwal A, Jatindera M,Wakhloo R,et al.Safety profile of various 5HT3 receptor antagonists used for PONV prophylaxis[J]. JK Science, 2016,18(2):111-115.
[21] 谭欣. 不同5-HT3 受体拮抗剂预防腹腔镜术后恶心呕吐的临床观察[J]. 比较哲学, 2014,11(35):345.